Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of neoadjuvant therapy by Nematode-NOSE(N-NOSE) using C. elegans

ABSTRACT: Primary outcome(s): ROC-ACU for IRC (chemotaxix index reduction score)

DISEASE(S): Esopahgeal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer

PROVIDER: 2656125 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Establishment and validation of risk assessment model for poor bowel cleansing in Beijing

Project description:Interventions: Gold Standard:Clinical outcomes;Index test:Risk assessment model for poor bowel cleansing&#32 Primary outcome(s): Boston bowel preparation score;SEN, SPE, ACC, AUC of ROC, PV+, PV-;SEN, SPE, ACC, AUC of ROC, PV+, PV- Study Design: Sequential

| 2701008 | ecrin-mdr-crc

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

Project description:PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared. Neoadjuvant validation cohort of 198 HER2-negative breast cancer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Response was assessed at the end of neoadjuvant treatment and distant-relapse-free survival was followed for at least 3 years post-surgery.

2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress

Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

Project description:PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared. Neoadjuvant study of 310 HER2-negative breast cancer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Response was assessed at the end of neoadjuvant treatment and distant-relapse-free survival was followed for at least 3 years post-surgery.

2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

2011-05-11 | GSE25065 | GEO

Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

2011-05-11 | GSE25055 | GEO

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Project description:We performed RNA-seq on pre-treatment endoscopic biopsies from 114 patients, including 97 patients treated with NAT that qualified for outcome analyses We then performed gene expression profiling analysis using data obtained from RNA-seq

2022-07-28 | GSE209746 | GEO

Identification and evaluation of biomarkers for screening and early diagnosis of colorectal neoplasms based on metabolomics

Project description:Interventions: Gold Standard:Colonoscopy findings;Index test:wide-target metabolites and lipid biomarkers Primary outcome(s): Sensitivity;Area under ROC curve Study Design: Factorial

| 2701069 | ecrin-mdr-crc

Evaluation of Invasive Breast Cancer Using a 12-Chemokine Gene Expression Score: Correlation With Clinical Outcomes

Project description:Clinically annotated GEPs of 366 primary resected breast tumors ranked by a 12 gene chemokine score

2017-12-31 | GSE86166 | GEO

Precision radiotherapy: Reduction in radiation for oropharyngeal cancer - the 30 ROC trial

Project description:Precision radiotherapy: Reduction in radiation for oropharyngeal cancer - the 30 ROC trial

| PRJNA661556 | ENA

The evaluation of diagnostic model of intestinal microbiome progressive markers for advanced adenoma and colorectal cancer

Project description:Interventions: Gold Standard:Pathologic diagnosis;Index test:diagnostic model of intestinal microbiome progressive markers&#32 Primary outcome(s): Sensitivity;The area under the ROC curve Study Design: Factorial

| 2701732 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data